Session » (2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2054

A Changing Paradigm: Reassessing the Role of Muscle Biopsy in Idiopathic Inflammatory Myopathies in a Single-Center Cohort

10:30AM-12:30PM: Abstract Number: 2053

A Prospective Study Unveils Damage Accrual and Myositis Specific Antibodies as Key Risk Factors for Mortality in Myositis

10:30AM-12:30PM: Abstract Number: 2059

Autoantibody Patterns in Myositis Immunoblot Testing: A Retrospective Study inInflammatory Myopathies and Connective Tissue Diseases (2017–2023)

10:30AM-12:30PM: Abstract Number: 2073

Cell-free DNA as a Potential Marker of Muscle Involvement and Treatment Response in Myositis

10:30AM-12:30PM: Abstract Number: 2070

Characterization of Hospitalization, Patient Demographics and Impact of Idiopathic Inflammatory Myopathies on Hospitalization Outcomes in Adult Fracture Patients: A National Inpatient Sample Analysis.

10:30AM-12:30PM: Abstract Number: 2057

Clinical Associations of Anti-Ro52 Antibodies in Idiopathic Inflammatory Myopathies: A Scoping Review

10:30AM-12:30PM: Abstract Number: 2068

Comparing characteristics, diagnostics, and treatment in people with different idiopathic inflammatory myopathies using a large representative cohort

10:30AM-12:30PM: Abstract Number: 2069

Concordance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies on subsequent myositis panel testing.

10:30AM-12:30PM: Abstract Number: 2055

Construct Validity of Total Improvement Score (TIS) as an Endpoint for Clinically Meaningful Improvement in Multiple Patient-Centered Outcome Measures in Dermatomyositis

10:30AM-12:30PM: Abstract Number: 2075

Ferritin trends differentiate anti-MDA5 Dermatomyositis from anti-Jo1 Antisynthetase Syndrome

10:30AM-12:30PM: Abstract Number: 2062

Immune Cell Signatures Associated with Disease Activity in Dermatomyositis Across Autoantibody Subtypes

10:30AM-12:30PM: Abstract Number: 2071

Impact of Diagnostic Delay on Disease Activity and Cumulative Damage in Patients with Idiopathic Inflammatory Myopathies in a Third-level Hospital in Mexico

10:30AM-12:30PM: Abstract Number: 2074

Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients

10:30AM-12:30PM: Abstract Number: 2064

Kinematics Underlying IBM-induced Dysphagia

10:30AM-12:30PM: Abstract Number: 2063

Linking PROMIS scores to disease severity and treatment in dermatomyositis: a patient-centered evaluation

10:30AM-12:30PM: Abstract Number: 2078

Neutrophil Extracellular Traps from Patients with Idiopathic Inflammatory Myopathies Induce Interferogenic Responses in Macrophages and Myeloid Dendritic Cells

10:30AM-12:30PM: Abstract Number: 2076

Nutritional Discourse in Online Myositis Communities: A Reddit Analysis of Patient-led Discussions

10:30AM-12:30PM: Abstract Number: 2058

Organ-specific disease activity and serological patterns in idiopathic inflammatory myopathies: A descriptive study in a Hispanic cohort

10:30AM-12:30PM: Abstract Number: 2065

Pain in Idiopathic Inflammatory Myopathies: A Global Study of Patient Experience

10:30AM-12:30PM: Abstract Number: 2067

Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors

10:30AM-12:30PM: Abstract Number: 2052

Prevalence of anti-neutrophil extracellular trap antibodies and their relationship with the clinical characteristics of patients with idiopathic inflammatory myopathies.

10:30AM-12:30PM: Abstract Number: 2066

Psychosocial Factors Strongly Influence Subjective Well-being in Patients with Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 2072

Results of an Integrated Program for Early Cancer Detection in Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 2077

Statin-Associated Immune-Mediated Necrotizing Myopathy in Native Americans

10:30AM-12:30PM: Abstract Number: 2056

Systematic Review: Nutritional Interventions in Muscle Diseases

10:30AM-12:30PM: Abstract Number: 2060

Treatment Patterns And Drug Use In Idiopathic Inflammatory Myopathies. Description Of The First Year After Diagnosis In A Swedish Myositis Cohort.

10:30AM-12:30PM: Abstract Number: 2061

Tryptophan Metabolism Alteration Is Associated With Rapidly Progressive Interstitial Lung Disease Of Anti-MDA5+ Dermatomyositis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].